| Autor: |
D, Urbanitz, H J, Pielken, P, Koch, T, Büchner, W, Hiddemann, A, Heinecke, F, Wendt, G, Maschmeier, J, van de Loo |
| Rok vydání: |
1985 |
| Předmět: |
|
| Zdroj: |
Onkologie. 8(3) |
| ISSN: |
0378-584X |
| Popis: |
102 patients with AML (leukemia after preleukemia, 2nd neoplasia included) were treated for remission induction by a modified TAD regimen in Munster; 55 patients (54%) achieved a complete remission (CR). For CR maintenance 40 patients were eligible for randomization according to the study protocol: cyclic chemotherapy (CT) alone vs. chemoimmunotherapy (CIT: plus allogeneic Neuraminidase-treated blasts in high dosage). 5 CR patients, induced identically in Essen, were randomized additionally. Evaluating all patients randomized there is only a marginally beneficial effect of CIT (21 patients) compared to CT (24 patients) concerning median survival (1020+ vs. 612 days) and relapse-free survival (494 vs. 380 days) until now. For patients receiving more than 2 cycles of maintenance therapy, however, CIT prolongs relapse-free survival significantly (930+ vs. 409 days; p = 0,02); that is also true for remission duration. This suggests that only repeated application of blasts may induce an immune response leading to a biologically relevant antileukemic effect. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
